🔗 Share this article

As America undertakes sweeping revisions to its vaccination schedules, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has focused upon potential deaths after Covid vaccination in her short tenure at the FDA.

Scheduled Changes to Pediatric Immunization Program

Agency leaders had intended to reveal sweeping changes to the pediatric immunization program recently, synchronizing the US with the Danish vaccine program, it is understood – a major change that would put the US out of alignment with much of the world with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for discontinuing specific childhood immunization guidelines in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

Høeg has little discernible background in pharmaceutical research, approval processes or leadership, which has been typical for previous leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for running the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the research of medication creation”, said Janet Woodcock. “Frankly, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an enormous range of responsibilities at the FDA, the former commissioner stated.

“The public just pays attention on the innovative therapies, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and other areas, and each of these need to be managed,” she said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a major administrative element to the job, which manages more than 5,000 employees. “It is a massive management job, if you perform it correctly,” the former official added.

Response and Disputed Policies

Regarding concerns about Dr. Høeg's credentials and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson responded that the “concerns stem from inaccurate premises”.

“Her resume is consistent with the responsibilities of her role,” the representative stated, pointing to the months Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial rapid medication authorization process that allegedly worried her preceding directors. “By what process are these drugs being selected for this fast-track system? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards more relaxed oversight of pharmaceuticals, except for shots.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, track record, Howard said. She published a analysis using unconfirmed public submissions to assess the frequency of myocarditis after Covid immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new federal leadership included revising guidelines for new vaccines and halting “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has reportedly floated the idea of excluding adolescent males from obtaining Covid vaccinations.

“She’s an thorough ideologue who starts off with her conclusions and reverse-engineers to accommodate the data in a very deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|